Rezolute (RZLT) Projected to Release Earnings on Thursday

Rezolute (NASDAQ:RZLT) is expected to announce its Q1 2027 results before the market opens on Thursday, November 5th. Analysts expect Rezolute to post earnings of ($0.18) per share and revenue of $1.12 million for the quarter. Individuals may visit the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). On average, analysts expect Rezolute to post ($0.63) EPS for the current fiscal year and ($0.40) EPS for the next fiscal year.

Rezolute Stock Performance

RZLT stock opened at $3.88 on Tuesday. The firm has a 50 day moving average of $4.23 and a 200-day moving average of $3.89. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.46.

Analysts Set New Price Targets

A number of research firms recently weighed in on RZLT. Lake Street Capital upped their target price on shares of Rezolute from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Thursday, October 15th. Citigroup restated a “market outperform” rating on shares of Rezolute in a research report on Thursday, October 15th. HSBC upgraded shares of Rezolute to a “buy” rating in a research report on Friday, September 25th. Finally, Citizens Jmp upped their price target on shares of Rezolute from $11.00 to $15.00 and gave the stock a “market outperform” rating in a report on Tuesday, October 6th. Twelve investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.22.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company’s lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.